









# Newsletter September 2019

**Hull & East Riding Prescribing Committee** 

For further information about HERPC documents go to:

http://www.hey.nhs.uk/herpc

For Joint Formulary go to

http://www.hey.nhs.uk/herpc/joint-formulary.htm

**Traffic Light Classification within HERPC:** 

RED – specialist prescriber only

AMBER – prescribed in accordance with approved shared care framework BLUE (Guideline or Specialist Led) – prescribed on advice of specialist or in line with national / local guideline

 $\label{eq:GREEN-other} \textbf{GREEN}-\textbf{other} \textbf{ items listed on formulary suitable for initiation and prescribing by any prescriber}$ 

## **ADDITIONS TO RED LIST**

**Guselkumab in line with TA521 Severe Plague Psoriasis** 

Durvalumab in line with TA578 for treating locally advanced unresectable non small cell lung cancer after platinum based chemoradiation

Tezacaftor/Ivacaftor/Elexacaftor for the treatment of cystic fibrosis

#### **NEW & UPDATED SCF**

**SCF Apomorphine Updated** 

**Methotrexate for Immunosuppression Updated** 

## **NEW & UPDATED GUIDELINES/SPECIALIST LED MEDICINES**

Aviptadil and Phentolamine (Invicorp) – for the treatment of erectile dysfunction

**Managing Diabetes Patients with Renal Disease** 

**Gastro Biologicals Pathway - Updated to include Tofacitinib** 

**Erectile Dysfunction Post RP Guideline - Update** 

**Formulary BGM Meters - Update** 

Sacubitral Valsartan Guideline - Update

Tolvaptan for the treatment of Autosomal Dominant Polycystic Kidney Disease Information for Primary Care

— Update

## **GREEN DRUGS**

Ciprofloxacin with Fluocinolone (Cetraxal Plus)- for acute otitis media/externa in patients with AOMT